CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.
The last earnings update was 43 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
CTI BioPharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
CTI BioPharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
CTI BioPharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
CTI BioPharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
CTI BioPharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Adam R. Craig, M.D., Ph.D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig served as Independent Consultant at CTI BioPharma Corp. since 2016 until March 20, 2017. Dr. Craig served as an Interim Chief Medical Officer at Immune Design Corp. since June 2016 until April 26, 2017. He has over 20 years of experience in hematology, oncology and drug development in both the US and Europe. He served as the Chief Medical Officer and Executive Vice President of Development at Sunesis Pharmaceuticals Inc. from March 1, 2012 to 2016. He oversaw the ongoing pivotal Phase 3 VALOR trial of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia (AML) and direct Sunesis’ global development program. He served as the Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd. from 2008 to 2012. He served as the Chief Medical Officer and Vice President of CytRx Oncology Corporation (formerly Innovive Pharmaceuticals, Inc.) from April 2005 to September 30, 2007. From December 17, 2003 to April 2005, he served as Vice President of Clinical Development and Medical Director of ArQule Inc. Dr. Craig joined ArQule from Ilex Oncology, Inc., where he was Senior Director of Clinical Development and Medical Director from April 2002 to December 2003. Prior to Ilex, Dr. Craig served as Medical Adviser in oncology at Antisoma, from March 2001 to March 2002. He served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig was a Medical Research Council Clinical Research Fellow from January 1998 to February 2001. Dr. Craig is a Member of the Royal College of Physicians (UK) and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from University of London’s Charing Cross and Westminster Medical School in July 1999 and holds a Ph.D. in Molecular Oncology from Leeds University in the U.K. in June 2001 and an MBA from the Open Business School, in the United Kingdom.
Insufficient data for Adam to compare compensation growth.
Adam's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the CTI BioPharma management team is less than 2 years, this suggests a new team.
Co-Founder & Consultant
Executive VP & COO
Senior Director of Investor Relations
Senior Vice President of US Commercial Operations
Senior Vice President Global Pharmaceutical Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the CTI BioPharma board of directors is less than 3 years, this suggests a new board.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.